Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Avadel Pharmaceuticals plc (AVDL)

7.38   -0.09 (-1.2%) 01-27 16:00
Open: 7.44 Pre. Close: 7.47
High: 7.61 Low: 7.312
Volume: 134,105 Market Cap: 456(M)

Technical analysis

as of: 2023-01-27 4:42:42 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 9.13     One year: 10.66
Support: Support1: 6.87    Support2: 6.28
Resistance: Resistance1: 7.81    Resistance2: 9.13
Pivot: 7.05
Moving Average: MA(5): 7.32     MA(20): 7.04
MA(100): 6.72     MA(250): 5.87
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 74.4     %D(3): 71.4
RSI: RSI(14): 54
52-week: High: 10.02  Low: 1.04
Average Vol(K): 3-Month: 638 (K)  10-Days: 416 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AVDL ] has closed below upper band by 21.2%. Bollinger Bands are 43.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.62 - 7.66 7.66 - 7.69
Low: 7.21 - 7.26 7.26 - 7.31
Close: 7.3 - 7.38 7.38 - 7.45

Company Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Headline News

Thu, 26 Jan 2023
Avadel Pharmaceuticals plc's (NASDAQ:AVDL) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - Simply Wall St

Wed, 25 Jan 2023
Avadel Pharmaceuticals PLC (AVDL) Stock: What Does the Chart Say Wednesday? - InvestorsObserver

Tue, 24 Jan 2023
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 -

Tue, 24 Jan 2023
2023-01-24 | NDAQ:AVDL | Press Release | Avadel ... - Stockhouse

Tue, 10 Jan 2023
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives Consensus ... - MarketBeat

Wed, 28 Dec 2022
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Director Buys ... - MarketBeat

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 62 (M)
Shares Float 44 (M)
% Held by Insiders 6.7 (%)
% Held by Institutions 51.5 (%)
Shares Short 3,920 (K)
Shares Short P.Month 3,990 (K)

Stock Financials

EPS -1.54
EPS Est Next Qtl -0.11
EPS Est This Year 1.15
EPS Est Next Year 0.25
Book Value (p.s.) -0.21
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -29.1
Return on Equity (ttm) -305.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.53
Qtrly Earnings Growth 0
Operating Cash Flow -77 (M)
Levered Free Cash Flow -40 (M)

Stock Valuations

PE Ratio -4.8
PEG Ratio -0.3
Price to Book value -36.91
Price to Sales 0
Price to Cash Flow -5.89

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.